Resolving disparities within the blood cancer space is a matter of “access to excellent healthcare,” according to Usama Gergis, MD, MBA.
Usama Gergis, MD, MBA
Advertisement
Articles by Usama Gergis, MD, MBA
Discrepancies in patients with blood cancer who are eligible for but do not undergo hematopoietic stem cell transplant have been observed not only for Black patients, but Hispanic, Asian, and White patients as well, according to Usama Gergis, MD, MBA.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Tarlatamab Plus Chemo/IO Regimens Are Safe, Elicit Responses in ES-SCLC
2
Tarlatamab Improves Survival Vs Chemotherapy in Second-Line SCLC Subgroups
3
Frontline Alectinib Upholds OS Benefit in Advanced ALK+ NSCLC
4
Pembrolizumab Combo Significantly Improves PFS/OS in Recurrent PROC
5
